Regarding potential competition such as NorthStar or SHINE Med: Basically, the non-reactor technologies have very poor unit economics. The product is less pure (which is fun to say in the context that we're talking about "molly"), and the electricity costs alone for operating accelerators is on par with just purchasing nuclear fuel. And, for the same "fuel" costs, eight of the SHINE accelerators will produce about 4% of a single Atomic Alchemy reactor.
NorthStar's approach of converting Mo-98 to Mo-99 works, but is very inefficient from a nuclear physics standpoint, and requires the same chemical processing, if not more, due to its low purity. It's a band-aid and won't really be able to compete once more players enter the market.
I guess another way to put it is this: the common thread between everyone in the article (except BWXT) is that they are relying on government $$$, and government money is never free. The govt. $$$ is given out on the condition it be used for developing "alternative technologies." And it just so happens that most of these alternative ways are either inferior from a unit economics standpoint, or are a costly regulatory nightmare because licensing new nuclear technology is simply a nightmare.
Regarding demand elasticity: Demand is actually dropping every year as the supply decreases. The weekly demand for the largest market share of radioisotopes is about 3/4 of what it was earlier this decade. As the population around the world grows and ages, the demand will continue to grow. If the myriad other radioisotopes used in nuclear medicine were more abundant and had a more stable supply, the demand for them, from what I can tell, would skyrocket. So there is a ton of room to grow JUST TO MEET CURRENT DEMAND. If China and India were to use nuclear medicine on the same per capita basis that the United States does, the world market would double and then triple, respectively.